Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic side effects of immunotherapy. We hypothesize that local delivery of mitazalimab at the time of IRE in patients with locally advanced pancreatic cancer will be safe, augment the immune effects of IRE, and decrease the risk of recurrence.

Trial Details

NCT ID
NCT06205849
Phase
PHASE1
Sponsor
University of California, San Diego
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • IRE + intratumoral mitazalimab (CD40 antibody) injection
  • NanoKnife
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742

Key Eligibility Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Histologically/cytologically-confirmed pancreatic ductal adenocarcinoma (PDAC)
  • Persons, aged \> 18 years of age, as PDAC is extremely rare in pediatric populations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →